Abstract
Subretinal injections in mice become increasingly important. Currently, the most prominent application is in gene therapy of inherited eye diseases by means of viral vector delivery to photoreceptors or the retinal pigment epithelium (RPE). Since there are no large animal models for most of these diseases, genetically modified mouse models are commonly used in preclinical proof-of-concept studies. However, because of the relatively small mouse eye, adverse effects of the subretinal delivery procedure itself may interfere with the therapeutic outcome. The protocol described here concerns a transscleral pars plana subretinal injection in small eyes, and may be used for but not limited to virus-mediated gene transfer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 5:333–338 (Review)
Marks WJ Jr, Ostrem JL, Verhagen L et al (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol 7:400–408
den Hollander AI, Black A, Bennett J (2010) Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest 120:3042–3053
Bainbridge JW, Smith AJ, Barker SS et al (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358:2231–2239
Bennett J, Ashtari M, Wellman J et al (2012) AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4, 120ra15
Jacobson SG, Cideciyan AV, Ratnakaram R et al (2012) Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130:9–24
Timmers AM, Zhang H, Squitieri A et al (2001) Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. Mol Vis 7:131–137
Johnson CJ, Berglin L, Chrenek MA et al (2008) Technical brief: subretinal injection and electroporation into adult mouse eyes. Mol Vis 14:2211–2226
Busskamp V, Duebel J, Balya D et al (2010) Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 329:413–417
Price J, Turner D, Cepko C et al (1987) Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A 84:156–160
Schlichtenbrede FC, da Cruz L, Stephens C et al (2003) Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy. J Gene Med 5:757–764
Alexander JJ, Umino Y, Everhart D et al (2007) Restoration of cone vision in a mouse model of achromatopsia. Nat Med 13:685–687
Janssen A, Min SH, Molday LL et al (2008) Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin-deficient mouse. Mol Ther 16:1010–1017
Cideciyan AV, Hauswirth WW, Aleman TS et al (2009) Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20:999–1004
Simonelli F, Maguire AM, Testa F et al (2010) Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18:643–650
Palfi A, Millington-Ward S, Chadderton N et al (2010) Adeno-associated virus-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. Hum Gene Ther 21:311–323
Sun X, Pawlyk B, Xu X et al (2010) Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther 17:117–131
Towne C, Setola V, Schneider BL et al (2011) Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol Ther 19:274–283
Lhériteau E, Libeau L, Mendes-Madeira A et al (2010) Regulation of retinal function but nonrescue of vision in RPE65-deficient dogs treated with doxycycline-regulatable AAV vectors. Mol Ther 18:1085–1093
Bainbridge JW, Mistry A, Schlichtenbrede FC et al (2003) Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina. Gene Ther 10:1336–1344
Liang FQ, Anand V, Maguire AM et al (2001) Intraocular delivery of recombinant virus. Methods Mol Med 47:125–139
Michalakis S, Mühlfriedel R, Tanimoto N et al (2010) Restoration of cone vision in the CNGA3−/− mouse model for congenital complete lack of cone photoreceptor function. Mol Ther 18:2057–2063
Acknowledgment
This work was supported by Deutsche Forschungsgemeinschaft (Se837/6-1, Se837/7-1).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Mühlfriedel, R., Michalakis, S., Garrido, M.G., Biel, M., Seeliger, M.W. (2012). Optimized Technique for Subretinal Injections in Mice. In: Weber, B., LANGMANN, T. (eds) Retinal Degeneration. Methods in Molecular Biology, vol 935. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-080-9_24
Download citation
DOI: https://doi.org/10.1007/978-1-62703-080-9_24
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-079-3
Online ISBN: 978-1-62703-080-9
eBook Packages: Springer Protocols